Summary
- Profile Type
- Business Offer
- POD Reference
- BOFI20240131011
- Term of Validity
- 5 February 2024 - 4 February 2026
- Company's Country
- Finland
- Type of partnership
- Commercial agreement
- Targeted Countries
- Latvia
- Netherlands
- Germany
- Denmark
- Czechia
- Spain
- Luxembourg
- Poland
- Belgium
- Sweden
- Brazil
- Switzerland
- France
- Estonia
- Canada
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- A Finnish SME develops and manufactures in-vitro diagnostic products, which enable multianalyte and rapid diagnosis of most common acute infections, such as respiratory, pharyngitis and gastrointestinal infections. The company is searching for large and middle-size in-vitro diagnostics companies to become new distributors and partners for localisation.
- Full Description
-
A Finnish SME, established 2005, develops and manufactures high quality diagnostic products and services especially for multianalyte and rapid diagnostics of acute infections. The unique platform enables automated and decentralised syndromic testing and health security screening of acute infections. The test panels cover viruses and bacteria for most common acute infections such as respiratory, pharyngitis and gastrointestinal infections. The streptococcous tests are the most sensitive in the world.
The SME already exports to several countries but it pursues new markets, more extensive distributor network, and fast growth.
The company has the following products:
1. A multianalyte test for acute upper and lower respiratory tract infections. The test system enables rapid detection and differentiation between viral and bacterial infections. (20 min preliminary result, 2 h final results)
• Influenza A and B viruses (H1N1v, H1N1, H3N2, H5N1, H7N9)
• Respiratory syncytial virus (A, B)
• Human metapneumovirus (A, B)
• Parainfluenza virus type 1-3
• Adenovirus
• Streptococcus pneumoniae
• SARS-CoV2
• Coronavirus OC43
2. A test for acute pharyngitis and tonsillitis. One can decide to choose a single analyte test, that reports results in 15 min with equal sensitivity to standard culture.
• Group A Streptococci
• Adenovirus
3.A multianalyte test for testing of acute gastroenteritis. The test system allows to run Gastro test and CDI (Clostridium difficile infection) test from the same patient sample.
• Norovirus GII.4
• Norovirus GI
• Rotavirus
• Adenovirus
• Campylobacter spp.
4. CDI (Clostridium difficile infection) test is designed to follow the ESCMID (European Society of Clinical Microbiology and Infectious Diseases) guideline for Clostridium difficile diagnostics. It allows simultaneous detection of the bacterium as well as the toxins A and B.
• GDH (bacterium surface protein)
• Toxins A/B
The company is looking for large and middle-size in vitro diagnostics companies to become new distributors and partners for localization. - Advantages and Innovations
-
The platform is a turn-key solution for prompt testing in the lab or in decentralized conditions. It combines specific antigen detection with an automated walk-away instrumentation. The accuracy of the platform is superior to lateral flow rapid tests, and similar to conventional laboratory tests such as ELISA or PCR (polymerase chain reaction).
The platform is LIS (laboratory information system) connectable, requires no lab expertise, and 3/4 of positive results are available in 20 minutes.
The platform is a time saving and cost-efficient solution for first-line diagnostics of acute respiratory tract infections (RTI) and gastroenteritis. The platform is continuous feed and it allows great capacity of >44 RTI samples or stool samples per work shift with minimal hands-on time.
The platform offers the greatest clinical value when operated near patient as an integrated part of the patient management process. - Technical Specification or Expertise Sought
- It is expected that the distributors sought have expertise in in-vitro diagnostics and channels to potential end customers who provide diagnostic analysis in healthcare.
- Stage of Development
- Already on the market
- Sustainable Development Goals
- Goal 3: Good Health and Well-being
- IPR status
- IPR granted
Partner Sought
- Expected Role of a Partner
- The Finnish SME is looking for distributors to be responsible for sales in their country or market area. The partners are also expected to take part in localising the products to their country or market area.
- Type and Size of Partner
- Big company
- SME 50 - 249
- Type of partnership
- Commercial agreement
Dissemination
- Technology keywords
- 06001005 - Diagnostics, Diagnosis
- 06002001 - Biochemistry / Biophysics
- 06001018 - Virus, Virology/Antibiotics/Bacteriology
- Market keywords
- 05001002 - In-vitro diagnostics
- 05001005 - Molecular diagnosis
- 05001001 - Diagnostic services
- 05001007 - Other diagnostic
- Sector Groups Involved
- Health
- Targeted countries
- Latvia
- Netherlands
- Germany
- Denmark
- Czechia
- Spain
- Luxembourg
- Poland
- Belgium
- Sweden
- Brazil
- Switzerland
- France
- Estonia
- Canada
Images
Files
Brochure
Videos
Test system and rapid workflow